Portal de Periódicos da CAPES

Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐19

2021; Elsevier BV; Volume: 5; Issue: 2 Linguagem: Inglês

10.1002/rth2.12486

2475-0379

Alex C. Spyropoulos, Stuart L. Cohen, Eugenia Gianos, Nina Kohn, Dimitrios Giannis, Saurav Chatterjee, Mark Goldin, Marty Lesser, Kevin Coppa, Jamie S. Hirsch, Thomas McGinn, Matthew A. Barish,

COVID-19 and healthcare impacts

Antithrombotic guidance statements for hospitalized patients with coronavirus disease 2019 (COVID-19) suggest a universal thromboprophylactic strategy with potential to escalate doses in high-risk patients. To date, no clear approach exists to discriminate patients at high risk for venous thromboembolism (VTE).